Transcript Dia 1

Novel Technologies to assess
Gut Health Claims for
Carbohydrates
Subthema: 2 - Characterization of biological
effects of carbohydrates
Naam trekker: UJF Tietge / HJ Verkade
Affiliatie: UMC Groningen/Dept. of Pediatrics
Contactgegevens: [email protected]
We are programmmed for disease
breast milk
vs.
formula feeding
in utero
aging
disease
programming
programming
e.g. SCFA
food
microbiota
gut health
e.g. SCFA
food
microbiota
e.g. SCFA
food
microbiota
- direct effects
- modulation of programmed risk
General theme: different carbohydrates have differential effects on the balance between
health and disease by affecting the intestine at all stages of life
Increasing gut health with carbohydrates at all stages of life
Human studies
Mouse models
programming
Gut-flora-dependent
metabolism of dietary PC and atherosclerosis
•• in
in vivo
vivo screening
screening routine for
platform
CHs
with human relevance
conventional
vs.
germ-free
(13)CH
vs.
selective
re-constitution/
transplantation
Deliverables
Deliverables
Disease models:
- atherosclerosis
Short-term
intervention:
- diabetes
(type I and II)
- children
(lean/obese)
- NAFLD/NASH
- adults
(young/elderly/IBD)
- intest. Inflammation
Techniques:
Techniques:
- atherosclerosis quantitation
- GTT/clamp
- GTT/ITT/clamps
- biomarkers
- Histology
-stable
isotope techniques
histology/clinical
symptoms
SCFA
measurements
ZN Wang et al. Nature
472, 57-63 (2011)
- stable isotopessymptoms
to quantitate
- histology/clinical
metabolic
fluxes
- sampling capsule to characterize:
- characterization
• microbiota microbiota
- barrier
function
• barrier
function
Close links to themes 1, 3 and 4
•• biomarkers
health claims based on
(disease-causing
signatures
established mechanisms
of metabolites/ bacterial
• products)
novel biomarkers of disease
including microbiota
• novel CHs to test in humans
• establish novel CHs as
• functional
leads for health
food claims
Increasing gut health with carbohydrates at all stages of life
Mouse models
programming
Deliverables
• in vivo screening
platform
conventional
vs.
germ-free
(13)CH
vs.
selective
re-constitution/
transplantation
Disease models:
- atherosclerosis
- diabetes (type I and II)
- NAFLD/NASH
- intest. Inflammation
• biomarkers
(disease-causing signatures
of metabolites/ bacterial
products)
• novel CHs to test in humans
• leads for health claims
Techniques:
- atherosclerosis quantitation
- GTT/ITT/clamps
- Histology
- histology/clinical symptoms
- stable isotopes to quantitate
metabolic fluxes
- characterization microbiota
- barrier function
Gut-flora-dependent metabolism of dietary PC and atherosclerosis
ZN Wang et al. Nature 472, 57-63 (2011)
Human studies
Deliverables
• in vivo screening routine for
CHs with human relevance
(13)CH
Short-term intervention:
- children (lean/obese)
- adults (young/elderly/IBD)
• health claims based on
established mechanisms
• novel biomarkers of disease
including microbiota
• establish novel CHs as
functional food
Techniques:
- GTT/clamp
- biomarkers
- stable isotope techniques
- SCFA measurements
- histology/clinical symptoms
- sampling capsule to characterize:
• microbiota
• barrier function